YARW NASDAQ
Yarrow Bioscience Inc
1W: -0.5%
1M: -16.2%
3M: -33.9%
YTD: -42.9%
$20.12
+0.12 (+0.60%)
Weekly Expected Move ±11.7%
$15
$17
$19
$22
$24
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$187.2M
52W Range16.04-46.95
Volume231,112
Avg Volume17,939
Beta2.08
Dividend$20.10
Analyst Ratings
Company Info
CEORebecca Velez Frey
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2026-07-28
Websiteyarrowbioscience.com
470 James Street, Suite 007
New Haven, CT 06513
US
New Haven, CT 06513
US
About Yarrow Bioscience Inc
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RTW Fund Group GP, L | J-Other | 133,290 | — | 2026-07-29 |
| RTW Fund Group GP, L | 0 | — | 2026-07-27 | |
| PERCEPTIVE ADVISORS | 0 | — | 2026-07-27 | |
| PERCEPTIVE ADVISORS | 967,360 | $0.00 | 2026-07-27 | |
| ORBIMED ADVISORS LLC | 0 | — | 2026-07-27 |